<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083030</url>
  </required_header>
  <id_info>
    <org_study_id>Pac 12</org_study_id>
    <nct_id>NCT01083030</nct_id>
  </id_info>
  <brief_title>Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis</brief_title>
  <acronym>PACIFIER</acronym>
  <official_title>Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is correlating efficacy of the treatment to the proportion of
      paclitaxel-dose supplied by the catheter. Forty-five patients each will be treated by
      paclitaxel-coated or uncoated conventional balloon catheters in randomized order in 3 study
      centers. Main inclusion criteria are Rutherford class 2 - 5, ≥70% stenosis or occlusion in
      the superficial femoral or popliteal artery, main exclusion criteria are related to the use
      of paclitaxel and the need for follow-up examinations. Either clinical or angiographic
      follow-up examinations are planned 6, 12 and 24 months following the intervention. Primary
      endpoint is 6-month angiographic late lumen loss. Secondary endpoints are further
      angiographic and clinical efficacy and various safety criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paclitaxel-coated balloons have been shown to reduce late lumen loss, restenosis rates and
      the need for repeat target lesion revascularization compared to conventional uncoated balloon
      catheters. The aim of the study is correlating efficacy of the treatment to the proportion of
      paclitaxel-dose supplied by the catheter. To this end paclitaxel loss of catheters in the
      introductory sheaths and residual paclitaxel on used balloons will be determined and
      correlated to individual data indicating inhibition of neointimal proliferation. According to
      the study protocol 45 patients each will be treated by paclitaxel-coated or uncoated
      conventional balloon catheters in randomized order in 3 study centers. Main inclusion
      criteria are Rutherford class 2 - 5, ≥70% stenosis or occlusion in the superficial femoral or
      popliteal artery, 3 to 30 cm of length; beyond common contraindications against PTA main
      exclusion criteria are related to the use of paclitaxel and the need for follow-up
      examinations. Patients will be blinded against treatment. Blinding of investigators after
      assignment of a patient to a treatment is not possible due to differences in the appearance
      of coated and uncoated catheters. Either clinical or angiographic follow-up examinations are
      planned 6, 12 and 24 months following the intervention. Primary endpoint is 6-month
      angiographic late lumen loss evaluated by a blinded independent core lab. Secondary endpoints
      are interventional success rate, restenosis rates, minimal lumen diameter, target lesion
      revascularization, change in Rutherford class, change in ankle-brachial-index, major
      amputations, a composite safety endpoint (defined as MAE =death of any cause, target limb
      amputation, clinically / DUS driven TLR) and all kinds of serious adverse events possibly
      related to the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late lumen loss</measure>
    <time_frame>6 months</time_frame>
    <description>Efficacy of paclitaxel coated percutaneous transluminal angioplasty (PTA) balloons in inhibiting restenosis of femoropopliteal arteries (late lumen loss)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical efficacy measures</measure>
    <time_frame>6 months</time_frame>
    <description>Various angiographic and clinical efficacy measures, safety and tolerance of paclitaxel coated PTA balloons in inhibiting restenosis of femoropopliteal arteries:
Target lesion revascularization (Target lesion revascularization is defined as any reintervention or artery bypass graft surgery involving the target lesion.)
Change in Rutherford stage compared to pretreatment
Major amputations at the index limb
Pre-defined event free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Conventional PTA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Angioplasty of SFA with uncoated balloon catheters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug coated balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Angioplasty of SFA with paclitaxel-coated balloon catheters</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous transluminal angioplasty (PTA)</intervention_name>
    <description>Angioplasty of superficial femoral artery (SFA)</description>
    <arm_group_label>Conventional PTA</arm_group_label>
    <arm_group_label>Drug coated balloon</arm_group_label>
    <other_name>uncoated PTA</other_name>
    <other_name>drug coated PTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with PAOD, Rutherford stage 2-5, Occlusion or stenosis &gt;70% in diameter
             of at least 3 cm length in the superficial femoral artery and/ or popliteal artery

        Exclusion Criteria:

          -  Acute thrombus or aneurysm in the index limb/ vessel

          -  Doubts in the willingness or capability of the patient to allow follow up examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Werk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martin-Luther-Hospital Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vivantes - Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Hubertus Hospital Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Hospital Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14193</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2008 Oct;97(10):773-81. doi: 10.1007/s00392-008-0682-5. Epub 2008 Jun 5.</citation>
    <PMID>18536865</PMID>
  </reference>
  <reference>
    <citation>Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008 Feb 14;358(7):689-99. doi: 10.1056/NEJMoa0706356.</citation>
    <PMID>18272892</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. Epub 2006 Nov 13.</citation>
    <PMID>17101615</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004 Aug 17;110(7):810-4. Epub 2004 Aug 9.</citation>
    <PMID>15302790</PMID>
  </reference>
  <reference>
    <citation>Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008 Sep 23;118(13):1358-65. doi: 10.1161/CIRCULATIONAHA.107.735985. Epub 2008 Sep 8. Erratum in: Circulation. 2008 Oct 14;118(16):e670.</citation>
    <PMID>18779447</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>July 25, 2013</last_update_submitted>
  <last_update_submitted_qc>July 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pAVK</keyword>
  <keyword>PTA</keyword>
  <keyword>drug coated balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

